Effects of pioglitazone or metformin on bone markers and bone mineral density as well as parameters of atherosclerosis in patients with type 2 diabetes
Not Applicable
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000001997
- Lead Sponsor
- Department of Internal Medicine 1, Shimane University School of Medicine
- Brief Summary
In the pioglitazone group bone mineral density at femoral neck and radius were significantly decreased, whereas the parameters of atherosclerosis were not changed. On the other hand, in the metformin group bone mineral density was not changed, whereas the parameters of atherosclerosis were significantly increased.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Nobody had hepatic or renal dysfunction or nutritional derangements. Patients treated with TZDs and metformin were excluded from this study. All patients were free of drugs known to influence bone and calcium metabolism, such as vitamin D, bisphosphonate, or estrogen, up until the time of the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method bone turnover marker, bone mineral density, intima-media thickness, pulse wave velocity
- Secondary Outcome Measures
Name Time Method